MD vs. AVTR: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical Services sector might want to consider either Pediatrix Medical Group (MD) or Avantor, Inc. (AVTR). But which of these two stocks offers value investors a better bang for their buck right now?
Broyhill's Q2 2024 Top Five Investments
Our top five investments—Avantor, Baxter, Fiserv, Nintendo, and Philip Morris—represented 50% of the equity portfolio, with mixed performance during the quarter. Avantor's shares rallied 26% in July after a strong earnings report, reaffirming full-year guidance and showing signs of industry recovery. Baxter's shares increased significantly post-earnings, demonstrating portfolio durability and organic growth, prompting us to accumulate shares at attractive valuations.
Avantor (AVTR) Inks Deal to Optimize Portfolio, Reduce Debt
Avantor's (AVTR) latest agreement is likely to enhance its focus on strategic growth opportunities and reduce its debt burden.
Avantor's (AVTR) Q2 Earnings Beat, Operating Margin Declines
Avantor's (AVTR) revenues decline in the second quarter with new segmental changes. Bioprocessing orders decline.
Avantor Analysts Increase Their Forecasts After Better-Than-Expected Earnings
Avantor, Inc. AVTR reported better-than-expected second-quarter earnings results on Friday.
Avantor, Inc. (AVTR) Q2 Earnings and Revenues Beat Estimates
Avantor, Inc. (AVTR) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.28 per share a year ago.
Analysts Estimate Avantor, Inc. (AVTR) to Report a Decline in Earnings: What to Look Out for
Avantor (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons Why You Should Hold Avantor (AVTR) Stock for Now
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
Avantor (AVTR) Launches Solutions for Gene Therapy Harvest
Avantor, Inc. AVTR recently released two innovative products aimed at revolutionizing the gene therapy harvest process. J.T.Baker Cell Lysis Solution and J.T.Baker Endonuclease are designed to enhance efficiency, reduce environmental impact, improve operational outcomes and preserve the integrity of viral particles.
Reasons Why You Should Retain Avantor (AVTR) Stock for Now
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
